CN103476769B - 抗癌剂 - Google Patents

抗癌剂 Download PDF

Info

Publication number
CN103476769B
CN103476769B CN201180059899.9A CN201180059899A CN103476769B CN 103476769 B CN103476769 B CN 103476769B CN 201180059899 A CN201180059899 A CN 201180059899A CN 103476769 B CN103476769 B CN 103476769B
Authority
CN
China
Prior art keywords
alkyl
compound
independently selected
compound according
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180059899.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103476769A (zh
Inventor
A.W.布格斯
F.沃克
K.G.沃森
H.威彻德
G.莱森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Publication of CN103476769A publication Critical patent/CN103476769A/zh
Application granted granted Critical
Publication of CN103476769B publication Critical patent/CN103476769B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180059899.9A 2010-10-27 2011-10-27 抗癌剂 Expired - Fee Related CN103476769B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40726510P 2010-10-27 2010-10-27
US61/407,265 2010-10-27
PCT/AU2011/001376 WO2012054978A1 (en) 2010-10-27 2011-10-27 Novel anti-cancer agents

Publications (2)

Publication Number Publication Date
CN103476769A CN103476769A (zh) 2013-12-25
CN103476769B true CN103476769B (zh) 2016-06-01

Family

ID=45992970

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180059899.9A Expired - Fee Related CN103476769B (zh) 2010-10-27 2011-10-27 抗癌剂

Country Status (12)

Country Link
US (3) US8835629B2 (enExample)
EP (1) EP2632916B1 (enExample)
JP (2) JP6184866B2 (enExample)
KR (1) KR101896924B1 (enExample)
CN (1) CN103476769B (enExample)
AU (1) AU2011320024B2 (enExample)
CA (1) CA2814120C (enExample)
ES (1) ES2621932T3 (enExample)
HU (1) HUE032522T2 (enExample)
NZ (1) NZ609186A (enExample)
PL (1) PL2632916T3 (enExample)
WO (1) WO2012054978A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835629B2 (en) * 2010-10-27 2014-09-16 The Walter And Eliza Hall Institute Of Medical Research Anti-cancer agents
KR101853785B1 (ko) 2013-11-20 2018-05-02 주식회사 만도 3상모터 제어장치 및 그의 고토크 유지 방법
WO2016070241A1 (en) * 2014-11-03 2016-05-12 Ctxt Pty Ltd Triazine compounds, compositions and synthesis
US20200128829A1 (en) * 2017-06-08 2020-04-30 University Of South Alabama Antimicrobial Compounds
MY205943A (en) 2018-01-17 2024-11-21 Aurigene Discovery Tech Ltd Substituted alkynylene compounds as anticancer agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
CN1697831A (zh) * 2002-09-23 2005-11-16 雷迪美国治疗公司 新三嗪化合物的制备方法和组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1035771A (enExample)
US2742466A (en) 1956-04-17 Chx n nhx c c
US3145203A (en) 1961-11-30 1964-08-18 Geigy Chem Corp Hydrazones of 5-nitro-2-furaldehyde
JPS5277163A (en) 1975-12-24 1977-06-29 Asahi Chem Ind Co Ltd Stabilized polyurethane composition
FR2524467A1 (fr) 1982-03-30 1983-10-07 Adir Polymethylene-imines disubstituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
JPS62192474A (ja) 1986-02-19 1987-08-24 Canon Inc 記録液
US4932998A (en) 1986-09-30 1990-06-12 Idemitsu Kosan Company Limited Triazine derivatives, and herbicides comprising the same as the effective ingredient
US4844731A (en) 1986-12-27 1989-07-04 Idemitsu Company Co., Ltd. Triazine derivatives
US5187045A (en) 1988-09-07 1993-02-16 Minnesota Mining And Manufacturing Company Halomethyl-1,3,5-triazines containing a sensitizer moiety
ATE142630T1 (de) 1989-02-20 1996-09-15 Idemitsu Kosan Co Triazin-derivate und unkrautvertilgungsmittel daraus
US5536722A (en) 1991-11-12 1996-07-16 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
FR2757057A1 (fr) 1996-12-17 1998-06-19 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un derive silicie a fonction benzalmalonate et utilisations
FR2757056B1 (fr) 1996-12-17 2003-03-14 Oreal Compositions comprenant un derive de dibenzoylmethane, un derive de 1,3,5-triazine et un compose amide et utilisations
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
US6262053B1 (en) 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2002342018A1 (en) 2001-10-12 2003-04-28 New York University Trisubstituted triazines compounds with antitubulin activity
US8835629B2 (en) * 2010-10-27 2014-09-16 The Walter And Eliza Hall Institute Of Medical Research Anti-cancer agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574057A (en) * 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
CN1697831A (zh) * 2002-09-23 2005-11-16 雷迪美国治疗公司 新三嗪化合物的制备方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives;Mingfang Zheng et.al.;《Bioorganic & Medicinal Chemistry》;20061119;第15卷;第1818页Table3 *
Synthesis of 5-Amino-3-methylimidazolidine-2,4 -dione and 1,3,5-Triazine Derivatives as Analogues of the Alkaloids Naamidine A and G;Helen M. Witchard. et.al.;《Synthesis》;20101109;第24卷;第4313页scheme 2 *

Also Published As

Publication number Publication date
JP2013540778A (ja) 2013-11-07
CA2814120A1 (en) 2012-05-03
AU2011320024B2 (en) 2014-10-30
US20150045365A1 (en) 2015-02-12
US9221799B2 (en) 2015-12-29
US20160145243A1 (en) 2016-05-26
AU2011320024A1 (en) 2013-05-02
EP2632916A4 (en) 2014-04-23
KR101896924B1 (ko) 2018-09-10
EP2632916A1 (en) 2013-09-04
KR20130141554A (ko) 2013-12-26
ES2621932T3 (es) 2017-07-05
JP6184866B2 (ja) 2017-08-23
PL2632916T3 (pl) 2017-07-31
US8835629B2 (en) 2014-09-16
CA2814120C (en) 2018-08-07
HUE032522T2 (en) 2017-09-28
US20130261119A1 (en) 2013-10-03
EP2632916B1 (en) 2017-01-11
JP2017137323A (ja) 2017-08-10
CN103476769A (zh) 2013-12-25
WO2012054978A1 (en) 2012-05-03
NZ609186A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
TWI457337B (zh) 呋呫基苯并咪唑
CN105153122B (zh) [(吲哚-3-基)嘧啶-2-基]氨基苯基丙-2-烯酰胺衍生物及盐、制备方法、应用
JP7625141B2 (ja) Ｅｒｂｂ２の阻害剤としての縮合四環キナゾリン誘導体
CN105452236A (zh) 取代的苄基吡唑
HUE034807T2 (en) New quinoline-substituted compound
CN103476769B (zh) 抗癌剂
US20190100509A1 (en) Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
CN111763215A (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
JP7201800B2 (ja) Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物
CN111362946A (zh) 一种药物化合物及其组合物和应用
CN110256408B (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
CN117164590B (zh) 稠合嘧啶类衍生物及其应用
JP2023155223A (ja) Ｋｒａｓ ｇ１２ｃ阻害剤及びオーロラａ阻害剤を含む治療方法
AU2014280992A1 (en) Novel Anti-Cancer Agents
CN116987073A (zh) 一种PI3Kα/HDAC6亚型选择性双重抑制剂及其应用
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑
US20220267336A1 (en) Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine
CN112480119A (zh) 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2004075563A (ja) 放射線増感剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160601